Renal Cell Carcinoma Metastasis to the Left Atrium

Only 13 cases of renal cell carcinoma metastasis to the left atrium of the heart have been described. We report the case of a man in his 50s who had undergone radical nephrectomy for renal cell carcinoma in 2006 and presented with amnesia at our neurology department in 2020. Magnetic resonance images of the brain showed metastatic lesions; subsequent computed tomograms of the chest, abdomen, and pelvis revealed a mass in the left atrium and multiple metastases in the lung, pleura, and pancreas. Our cardiologists advised against surgical removal of the left atrial mass because of a poor prognosis, so radiation therapy and immunotherapy were initiated instead.     

Gastric Varices due to Splenic Vein Occlusion with Left Renal Cell Carcinoma

Abstract: A 57-year-old man was admitted to our hospital in March 1994 with general fatigue and weight loss. Left renal carcinoma was diagnosed by ultrasonography and computed tomography (CT). The left renal carcinoma was too advanced to allow curative resection. Postoperatively, interferon therapy was administered for treatment of the renal cancer at the department of urology. In November 1994, he was admitted to our department with hematemesis. Recurrent left renal carcinoma and splenic vein occlusion were seen on CT. Endoscopic findings showed cardiofornical varices. We diagnosed rupture of gastric varices due to splenic vein occlusion with left renal carcinoma. Endoscopic injection sclerotherapy (EIS) was performed. After EIS, bleeding from the gastric varices resolved completely.     

The Influence of the Primary Tumor on the Long-term Results of Pulmonary Metastasectomy for Metastatic Renal Cell Carcinoma

Objective?To investigate one of the primary tumor (PT) on pulmonary metastasectomy (PM) for metastatic renal cell carcinoma (RCC) and to define prognostic factors.Methods?Retrospective review of patients with pulmonary metastases from RCC from January 1999 through December 2008 was performed. All patients underwent PM with curative intend. TNM-classification, tumor stage and PT grade, disease-free-interval (DFI) from nephrectomy to the diagnosis of metastasis, systemic chemotherapy before surgical intervention, surgical procedures, morbidity, mortality, and survival were investigated. Results?One-hundred seven consecutive patients (age 61.5 ± 9.6 years) underwent PM. Morbidity and mortality rates were 15.0 and 0.9%, respectively. Thirty-six patients (33.6%) had systematic therapy before PM. Complete resections could be achieved in 104 patients (97.2%). Mean survival was 63.4 ± 5.1 months. The overall 5- and 10-year survival rates were 47 and 9%, respectively. Advanced N-Status (p?相似文献   

Myxoma of the Left Ventricle

This report concerns a 69-year-old woman who presented with an asymptomatic myxoma in the left ventricle. The tumor was successfully excised. We provide a very brief review of 72 other published cases of surgically treated left ventricular myxoma.     

Pseudoaneurysm of the Left Ventricle

Abstract: A case study is reported of a patient with rheumatoid arthritis who developed a pseudoaneurysm of the left ventricle after inferior myocardial infarction. The clinical diagnosis was confirmed by radionuclide cardiac blood pool imaging and by contrast ventricu-lography; the aneurysm was successfully excised.     

血压平逆转肾性高血压大鼠左室重构的作用及机制

目的　探讨复方中药制剂血压平逆转二肾一夹 (2K1C)肾性高血压大鼠左室重构的作用及机制。方法　采用 2K1C法 ,建立肾性高血压大鼠 (RHR)模型 ,术后 8周将造模成功的 40只RHR随机分为 5组 ,每组 8只 ,采用放免法检测血清Ⅲ型前胶原(PCⅢ ) ,测量心肌细胞面积、周长、平均直径、长径和短径。SP免疫组化测量原癌基因C -myc和C -fos表达阳性细胞的平均光密度值。结果　①血压平有降低血压、左室重量 (LVW )、左室重量指数 (LVW /BW )、心肌细胞体积的作用 ;②血压平可降低血清PCⅢ含量 ,抑制原癌基因C -myc和C -fos的表达 ;③血压平的降压和逆转左室重构的药理作用有量效关系。结论　血压平具有逆转RHR左室重构的作用 ,其降低血压、降低血清PCⅢ含量、抑制Ⅲ型胶原合成、防治心肌纤维化及降低原癌基因C -myc和C -fos的表达、抑制心肌细胞肥大、减轻左心室肥厚 ,是其逆转2K1CRHR左室重构的部分机制。     

The Medical Treatment of Metastatic Renal Cell Cancer

Patients who present with or subsequently develop metastases from renal cell carcinoma still have a poor prognosis. However, in recent years the use of immunotherapy as either a single agent or in double or triple combinations has shown some welcome reproducible responses in this disease. Too much reliance, however, on phase II studies has tended to obscure the critical role of prognostic factors in the survival of patients with metastatic renal cell cancer. A critical analysis is offered with the current state of therapy and the exciting new fields of therapeutic research are discussed.     

Clinical Aspects of Renal Cell Carcinoma

Renal cell carcinoma (RCC) represents a heterogeneous group of tumors, the most common of which is clear cell adenocarcinoma. RCC accounts for 3% of adult tumors. The incidence has increased more than 30% over the past two decades. It is generally postulated that the increased incidence rates reflect earlier diagnosis at an earlier stage, largely due to more liberal use of radiological imaging techniques. However, advanced disease has also been diagnosed more frequently and the mortality rate has increased as well. Prevention of RCC should focus on smoking cessation and maintaining ideal body mass index. Familial forms of kidney cancer have been described on four distinct histological patterns: clear cell, papillary, chromophobe, and oncocytoma. Genetic forms afflict individuals at an earlier age with a multifocal and recurrent pattern; therefore, nephron-sparing procedures should be the treatment of choice for these patients. The yield of screening the general population for RCC is still relatively low and hence not cost-effective. Screening should be reserved for individuals who carry high risk for RCC. The classic triad of flank pain, macroscopic hematuria, and palpable abdominal mass is now detected in fewer than 10% of patients, and is a late sign. Today, most tumors are diagnosed incidentally. Paraneoplastic syndromes have been reported in 10–40% of patients and can be seen at any stage of disease. The indications and application of percutaneous biopsy for renal masses are limited and mainly used to make differential diagnosis with an infectious process, lymphoma and metastases to the kidney.